GLP-1 Agonists Reduce Anxiety and Depression
Analysis based on 24 articles · First reported Mar 18, 2026 · Last updated Mar 28, 2026
The study's findings suggest a significant positive impact on the pharmaceutical market, particularly for companies producing GLP-1 receptor agonists like Semaglutide and Liraglutide. Increased demand for Semaglutide and Semaglutide could arise from their newly identified mental health benefits, potentially leading to expanded indications and higher sales. This could also spur further research and development in the intersection of metabolic and mental health treatments.
A new study published in The Lancet Psychiatry, conducted by an international team from the University of Eastern Finland, Karolinska Institute, and Griffith University, has revealed that GLP-1 receptor agonists, commonly used for diabetes and obesity, may also reduce symptoms of anxiety and depression. The large registry-based study, involving nearly 100,000 participants in Sweden, found that Semaglutide (active ingredient in Semaglutide and Semaglutide) was associated with a 44% lower risk of worsening depression and a 38% decreased risk of worsening anxiety. It also showed a 47% lower risk of substance use disorders. Liraglutide (used in Liraglutide) also showed a reduced risk of worsening depression. While the exact mechanisms are unclear, potential factors include reduced alcohol consumption, improved body image from weight loss, better glycaemic control, and direct neurobiological effects. Researchers emphasize the need for controlled clinical trials to confirm these observational findings.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard